Latest News - Santen

Tuesday, April 25, 2017 | Clinical Trials, Santen

FDA Accepts Santen's NDA for Intravitreal Sirolimus in the Treatment of Noninfectious Uveitis of the Posterior Segment

Santen Pharmaceutical announced that the FDA has accepted for review the new drug application (NDA) for intravitreal sirolimus (440 µg), development code DE-109, for the treatment of noninfectio…

Read the full story

Thursday, February 23, 2017 | Glaucoma, Partnerships, Santen

Santen and twoXAR Announce Strategic Research Collaboration to Discover New Glaucoma Treatments

Santen and twoXAR, an artificial intelligence-driven biopharmaceutical company, announced that the two companies have entered into a strategic research collaboration focused on the identification of n…

Read the full story

Monday, November 28, 2016 | Clinical Trials, Santen

Santen Announces Phase 3 SAKURA Program Topline Results in Patients with Noninfectious Uveitis of the Posterior Segment

Santen Pharmaceutical announced the topline results of its SAKURA (Sirolimus Study Assessing Double-Masked Uveitis Treatment) global clinical development program designed to confirm the efficacy, safe…

Read the full story

Tuesday, July 19, 2016 | Acquisitions/Mergers, Glaucoma, InnFocus, Santen

Santen to Acquire InnFocus, Developer of MicroShunt Glaucoma Implant Device

Santen Pharmaceutical and InnFocus announced that the two companies have entered into a definitive agreement under which Santen will acquire privately held InnFocus, developer of the InnFocus MicroShu…

Read the full story

Friday, July 24, 2015 | Product Releases, Santen

Santen Launches Ikervis - The First and Only Ciclosporin Eye Drops Licensed in the UK

Santen UK Limited announced the launch of Ikervis (ciclosporin 1 mg/mL eye drops emulsion in single-dose containers) in the UK, according to a company news release. Ikervis is licensed for the…

Read the full story

Monday, May 04, 2015 | Partnerships, Clearside Biomedical , Santen

Clearside Biomedical and Santen Announce Research Collaboration in Glaucoma

Clearside Biomedical and Santen announced the expansion of their research collaboration to include the field of glaucoma. The two companies have been working together since January 2013 to develop dru…

Read the full story

Wednesday, March 25, 2015 | Santen

Santen Announces Approval of Ikervis for EU Marketing Authorization

Santen Pharmaceutical Co. announced it received approval of the Marketing Authorization Application (MAA) for Ikervis from the European Commission. Ikervis is approved for treatment of severe keratiti…

Read the full story

Monday, March 02, 2015 | Santen

EMA Accepts Santan's Marketing Application Filing for Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis of the Posterior Segment

Santen Pharmaceutical announced that the European Medicines Agency (EMA) has accepted the company’s marketing authorization application (MAA) filing for the use of intravitreal sirolimus, an inv…

Read the full story